| Year |
Citation |
Score |
| 2023 |
Smith BAH, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, Sullivan DK, Wisnovsky S, Stark JC, Pluvinage JV, Swaminathan S, Riley NM, Rajan A, Majeti R, Felsher DW, et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proceedings of the National Academy of Sciences of the United States of America. 120: e2215376120. PMID 36897988 DOI: 10.1073/pnas.2215376120 |
0.325 |
|
| 2022 |
Gong YY, Shao H, Li Y, Brafford P, Stine ZE, Sun J, Felsher DW, Orange JS, Albelda SM, Dang CV. Na/H-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells. Cancer Research Communications. 2: 842-856. PMID 36380966 DOI: 10.1158/2767-9764.crc-22-0270 |
0.316 |
|
| 2022 |
Sullivan DK, Deutzmann A, Yarbrough J, Krishnan MS, Gouw AM, Bellovin DI, Adam SJ, Liefwalker DF, Dhanasekaran R, Felsher DW. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes. Oncogene. PMID 36207533 DOI: 10.1038/s41388-022-02458-9 |
0.305 |
|
| 2021 |
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nature Reviews. Clinical Oncology. PMID 34508258 DOI: 10.1038/s41571-021-00549-2 |
0.358 |
|
| 2021 |
Mahauad-Fernandez WD, Rakhra K, Felsher DW. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia. Methods in Molecular Biology (Clifton, N.J.). 2318: 297-312. PMID 34019298 DOI: 10.1007/978-1-0716-1476-1_16 |
0.322 |
|
| 2021 |
Hori SS, Tong L, Swaminathan S, Liebersbach M, Wang J, Gambhir SS, Felsher DW. A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. Scientific Reports. 11: 1341. PMID 33446671 DOI: 10.1038/s41598-020-78947-2 |
0.373 |
|
| 2020 |
Dhanasekaran R, Park J, Yevtodiyenko A, Bellovin DI, Adam SJ, Kd AR, Gabay M, Fernando H, Arzeno J, Arjunan V, Gryanzov S, Felsher DW. MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. Molecular Therapy. Nucleic Acids. 21: 850-859. PMID 32805488 DOI: 10.1016/J.Omtn.2020.07.008 |
0.834 |
|
| 2020 |
Mahauad-Fernandez WD, Felsher DW. The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship? Cancer Research. PMID 32732221 DOI: 10.1158/0008-5472.Can-20-0787 |
0.414 |
|
| 2020 |
Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher DW. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications. 11: 2860. PMID 32503978 DOI: 10.1038/S41467-020-16447-7 |
0.37 |
|
| 2020 |
Smith MT, Guyton KZ, Kleinstreuer N, Borrel A, Cardenas A, Chiu WA, Felsher DW, Gibbons CF, Goodson WH, Houck KA, Kane A, La Merrill MA, Lebrec H, Lowe L, McHale CM, et al. The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32152214 DOI: 10.1158/1055-9965.Epi-19-1346 |
0.341 |
|
| 2020 |
Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, ... ... Felsher DW, et al. and cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Elife. 9. PMID 31933479 DOI: 10.7554/Elife.50731 |
0.79 |
|
| 2020 |
Mahauad-Fernandez W, Zlitni S, Bhatt A, Felsher D. Abstract B21: The gastrointestinal microbiota controls cancer cell intrinsic mechanisms to promote the progression of acute lymphoblastic leukemia Cancer Research. 80. DOI: 10.1158/1538-7445.Mvc2020-B21 |
0.494 |
|
| 2019 |
Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports. 9: 16775. PMID 31727951 DOI: 10.1038/S41598-019-53290-3 |
0.417 |
|
| 2019 |
Gouw AM, Margulis K, Liu NS, Raman SJ, Mancuso A, Toal GG, Tong L, Mosley A, Hsieh AL, Sullivan DK, Stine ZE, Altman BJ, Schulze A, Dang CV, Zare RN, ... Felsher DW, et al. The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. Cell Metabolism. PMID 31447321 DOI: 10.1016/J.Cmet.2019.07.012 |
0.501 |
|
| 2019 |
Das B, Pal B, Bhuyan R, Li H, Sarma A, Gayan S, Talukdar J, Sandhya S, Bhuyan S, Gogoi G, Gouw AM, Baishya D, Gotlib JR, Kataki AC, Felsher DW. MYC regulates the HIF-2α stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Research. PMID 31266772 DOI: 10.1158/0008-5472.Can-18-2847 |
0.368 |
|
| 2019 |
Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, Hawke DH, Felsher D, Narla G, Lu Z, Lee RT. Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Scientific Reports. 9: 6428. PMID 31015523 DOI: 10.1038/S41598-019-41444-2 |
0.414 |
|
| 2019 |
Dhanasekaran R, Felsher DW. A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC). Hepatology (Baltimore, Md.). PMID 30958566 DOI: 10.1002/Hep.30649 |
0.309 |
|
| 2019 |
Struntz NB, Chen A, Deutzmann A, Wilson RM, Stefan E, Evans HL, Ramirez MA, Liang T, Caballero F, Wildschut MHE, Neel DV, Freeman DB, Pop MS, McConkey M, Muller S, ... ... Felsher DW, et al. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. Cell Chemical Biology. PMID 30880155 DOI: 10.1016/J.Chembiol.2019.02.009 |
0.386 |
|
| 2019 |
Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Kd AR, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, ... ... Felsher DW, et al. Author response: MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity Elife. DOI: 10.7554/Elife.50731.Sa2 |
0.772 |
|
| 2019 |
Swaminathan S, Heftdal LD, Liefwalker D, Dhanasekaran R, Deutzmann A, Horton C, Mosley A, Liebersbach M, Gentles A, Maecker HT, Felsher D. MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling Blood. 134: 730-730. DOI: 10.1182/Blood-2019-122607 |
0.414 |
|
| 2018 |
Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 6: 125. PMID 30458889 DOI: 10.1186/S40425-018-0431-X |
0.774 |
|
| 2018 |
Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B, Schulze A. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene. PMID 29872221 DOI: 10.1038/S41388-018-0315-Z |
0.385 |
|
| 2018 |
Casey SC, Baylot V, Felsher DW. The MYC Oncogene is a Global Regulator of the Immune Response. Blood. PMID 29514782 DOI: 10.1182/Blood-2017-11-742577 |
0.438 |
|
| 2018 |
Dhanasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, Zabludoff S, Li J, Kaimal V, Karmali P, Felsher DW. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget. 9: 5517-5528. PMID 29464015 DOI: 10.18632/Oncotarget.22342 |
0.324 |
|
| 2018 |
Swaminathan S, Heftdal LD, Liefwalker DF, Dhanasekaran R, Deutzmann A, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher D. MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies Blood. 132: 2619-2619. DOI: 10.1182/Blood-2018-99-110472 |
0.335 |
|
| 2017 |
Poole CJ, Zheng W, Lodh A, Yevtodiyenko A, Liefwalker D, Li H, Felsher DW, van Riggelen J. DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. Oncotarget. 8: 76898-76920. PMID 29100357 DOI: 10.18632/Oncotarget.20176 |
0.421 |
|
| 2017 |
Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, Felsher DW. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunology, Immunotherapy : Cii. PMID 28905118 DOI: 10.1007/S00262-017-2059-Y |
0.377 |
|
| 2017 |
Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, ... Felsher DW, et al. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nature Communications. 8: 15770. PMID 28593993 DOI: 10.1038/Ncomms15770 |
0.408 |
|
| 2017 |
Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 28400509 DOI: 10.1073/Pnas.1617709114 |
0.346 |
|
| 2017 |
Casey SC, Baylot V, Felsher DW. MYC: Master Regulator of Immune Privilege. Trends in Immunology. PMID 28233639 DOI: 10.1016/J.It.2017.01.002 |
0.445 |
|
| 2017 |
Pal B, Sarma A, Talukdar J, Bhuyan S, Sandhya S, Gayan S, Gogoi G, Baishya D, Kataki AC, Felsher DW, Das B. Abstract 42: MYC through HIF-2α regulates the altruistic stemness program in human leukemia stem cells Clinical Cancer Research. 23: 42-42. DOI: 10.1158/1557-3265.Hemmal17-42 |
0.392 |
|
| 2017 |
Li Y, Deutzmann A, Bell J, Ji H, Felsher D. Abstract PR02: Synthetic lethality screen identifies novel druggable targets in the MYC pathway Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr02 |
0.451 |
|
| 2017 |
Swaminathan S, Mosley A, Horton C, Liefwalker DF, Deutzmann A, Dhanasekaran R, Gouw A, Gentles A, Eilers M, Maecker HT, Felsher DW. Abstract 2943: MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies Cancer Research. 77: 2943-2943. DOI: 10.1158/1538-7445.Am2017-2943 |
0.335 |
|
| 2016 |
Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. PMID 27095570 DOI: 10.18632/Oncotarget.8731 |
0.395 |
|
| 2016 |
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw A, Baylot V, Guetegemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science (New York, N.Y.). PMID 26966191 DOI: 10.1126/Science.Aac9935 |
0.36 |
|
| 2016 |
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, ... Felsher DW, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. PMID 26934227 DOI: 10.1038/Nature16969 |
0.3 |
|
| 2016 |
Gouw AM, Toal GG, Felsher DW. Metabolic vulnerabilities of MYC-induced cancer. Oncotarget. PMID 26863454 DOI: 10.18632/Oncotarget.7223 |
0.374 |
|
| 2016 |
Hebb JPO, Mosley A, Vences Catalan F, Ellmark P, Norlen P, Felsher DW. Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model Blood. 128: 4172-4172. DOI: 10.1182/Blood.V128.22.4172.4172 |
0.416 |
|
| 2016 |
Pal B, Bayat-Mokhtari R, Li H, Bhuyan R, Talukdar J, Sandhya S, Sarma A, Tasabehji W, Bhuyan S, Gayan S, Kataki AC, Baishya D, Yeger H, Felsher DW, Das B. Abstract 251: Stem cell altruism may serve as a novel drug resistance mechanism in oral cancer Cancer Research. 76: 251-251. DOI: 10.1158/1538-7445.Am2016-251 |
0.402 |
|
| 2016 |
Taparra K, Wang H, Nugent K, Malek R, Groves J, Yildirir G, Simons B, Felsher D, Zachara N, Tran P. Abstract 1054: SNAI1 regulates the hexosamine biosynthetic pathway to promote tumorigenesis and oncogene-induced senescence escape in lung cancer Cancer Research. 76: 1054-1054. DOI: 10.1158/1538-7445.Am2016-1054 |
0.485 |
|
| 2015 |
Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, Gouw AM, Venkataraman A, Li B, Goraksha-Hicks P, Diskin SJ, Bellovin DI, Simon MC, Rathmell JC, Lazar MA, ... ... Felsher DW, et al. MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metabolism. 22: 1009-19. PMID 26387865 DOI: 10.1016/J.Cmet.2015.09.003 |
0.399 |
|
| 2015 |
Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, ... ... Felsher DW, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis. 36: S254-96. PMID 26106142 DOI: 10.1093/Carcin/Bgv039 |
0.303 |
|
| 2015 |
Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran C, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, ... ... Felsher DW, et al. The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis. 36: S160-83. PMID 26106136 DOI: 10.1093/Carcin/Bgv035 |
0.443 |
|
| 2015 |
Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, Casey SC, Li Y, Dang CV, Zare RN, Felsher DW. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proceedings of the National Academy of Sciences of the United States of America. 112: 6539-44. PMID 25964345 DOI: 10.1073/Pnas.1507228112 |
0.805 |
|
| 2015 |
Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, ... ... Felsher DW, et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. The Journal of Clinical Investigation. 125: 2293-306. PMID 25915584 DOI: 10.1172/Jci75836 |
0.532 |
|
| 2015 |
Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, ... ... Felsher DW, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology. PMID 25865775 DOI: 10.1016/J.Semcancer.2015.02.007 |
0.488 |
|
| 2015 |
Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget. 6: 3563-77. PMID 25784651 DOI: 10.18632/Oncotarget.2969 |
0.454 |
|
| 2015 |
Ma C, Han M, Terabe M, Berzofsky J, Felsher D, Greten T. Abstract B44: The role of CD4 T cells in murine model of NASH-promoted HCC Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B44 |
0.353 |
|
| 2015 |
Das B, Li H, Bhuyan R, Felsher DW. Abstract PR14: HIF-2alpha regulates self-renewal of MYC dependent cancer stem cells Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr14 |
0.395 |
|
| 2015 |
Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. Abstract PR13: miR-17-92 mediates MYC oncogene addiction Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr13 |
0.363 |
|
| 2015 |
Felsher D. Abstract IA12: Mechanisms of MYC addiction Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Ia12 |
0.518 |
|
| 2015 |
Casey SC, Do RK, Felsher DW. Abstract B02: The role of the immune system in sustained tumor regression following oncogene inactivation Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B02 |
0.492 |
|
| 2015 |
Koch D, Adams S, Gentles A, Anchang B, Sullivan D, Plevritis S, Felsher D. Abstract A48: Gene expression signatures associated with MYC oncogene addiction in lymphoma Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A48 |
0.422 |
|
| 2015 |
Li Y, Seita J, Felsher D, Dill D. Abstract A2-35: Discovery of differentiation therapeutics using a systems biology approach Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-35 |
0.44 |
|
| 2015 |
Li Y, Seita J, Felsher D, Dill DL. Abstract B2-12: A systems biology approach for the discovery of differentiation therapeutics Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-12 |
0.441 |
|
| 2015 |
Ma C, Felsher D, Greten T. Abstract 3166: The role of CD4 T cells in murine model of NASH-promoted HCC Cancer Research. 75: 3166-3166. DOI: 10.1158/1538-7445.Am2015-3166 |
0.36 |
|
| 2015 |
Li H, Talukdar J, Sandhya S, Bhuyan S, Gayan S, Sarma A, Mokhtari RB, Felsher DW, Yeger H, Das B. Abstract 1529: MYC and HIF-2alpha cooperates in oral squamous carcinoma cell self-renewal during hypoxia Cancer Research. 75: 1529-1529. DOI: 10.1158/1538-7445.Am2015-1529 |
0.421 |
|
| 2014 |
Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 5: 7986-7. PMID 25275297 DOI: 10.18632/Oncotarget.2474 |
0.477 |
|
| 2014 |
Li Y, Choi PS, Casey SC, Felsher DW. Activation of Cre recombinase alone can induce complete tumor regression. Plos One. 9: e107589. PMID 25208064 DOI: 10.1371/Journal.Pone.0107589 |
0.406 |
|
| 2014 |
Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 26: 262-72. PMID 25117713 DOI: 10.1016/J.Ccr.2014.06.014 |
0.329 |
|
| 2014 |
Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. Journal For Immunotherapy of Cancer. 2: 24. PMID 25089198 DOI: 10.1186/2051-1426-2-24 |
0.503 |
|
| 2014 |
Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proceedings of the National Academy of Sciences of the United States of America. 111: E3316-24. PMID 25071175 DOI: 10.1073/Pnas.1406123111 |
0.466 |
|
| 2014 |
Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proceedings of the National Academy of Sciences of the United States of America. 111: 10450-5. PMID 24994904 DOI: 10.1073/Pnas.1409778111 |
0.776 |
|
| 2014 |
Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harbor Perspectives in Medicine. 4. PMID 24890832 DOI: 10.1101/Cshperspect.A014241 |
0.824 |
|
| 2014 |
Casey SC, Li Y, Felsher DW. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunologic Research. 58: 282-91. PMID 24791942 DOI: 10.1007/S12026-014-8503-6 |
0.476 |
|
| 2014 |
Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher DW, Shido K, Rafii A, Scandura JM, Rafii S. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 25: 350-65. PMID 24651014 DOI: 10.1016/J.Ccr.2014.02.005 |
0.443 |
|
| 2014 |
Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis Journal of Internal Medicine. 276: 52-60. PMID 24645771 DOI: 10.1111/Joim.12237 |
0.468 |
|
| 2014 |
Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small (Weinheim An Der Bergstrasse, Germany). 10: 566-75, 417. PMID 24038954 DOI: 10.1002/Smll.201301456 |
0.409 |
|
| 2014 |
Li Y, Seita J, Felsher DW, Dill D. Leukemia Cell Differentiation upon Targeted Therapy Revealed By a Systems Biology Approach Blood. 124: 5202-5202. DOI: 10.1182/Blood.V124.21.5202.5202 |
0.37 |
|
| 2014 |
Altman BJ, Hsieh A, Gouw AM, Stine ZE, Venkataraman A, Bellovin DI, Diskin SJ, Lu W, Zhang S, Felsher DW, Maris JM, Lazar MA, Rabinowitz JD, Hogenesch JB, Dang CV. Abstract 2953: Rev-erbα modulates Myc-driven cancer cell growth and altered metabolism Cancer Research. 74: 2953-2953. DOI: 10.1158/1538-7445.Am2014-2953 |
0.464 |
|
| 2014 |
Hsieh AL, Altman BJ, Venkataraman A, Bellovin DI, Felsher DW, Hogenesch JB, Dang CV. Abstract 1419: Oncogenic Myc disrupts NAMPT circadian oscillation in mouse hepatocellular carcinoma cell line Cancer Research. 74: 1419-1419. DOI: 10.1158/1538-7445.Am2014-1419 |
0.47 |
|
| 2014 |
Hsieh A, Altman B, Stine Z, Gouw A, Venkataraman A, Li B, Goraksha-Hicks P, Diskin S, Bellovin D, Celeste Simon M, Rathmell J, Lazar M, Maris J, Felsher D, Hogenesch J, et al. TM-06 * MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS Neuro-Oncology. 16: v214-v214. DOI: 10.1093/Neuonc/Nou278.6 |
0.479 |
|
| 2014 |
Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE. Cancer Therapy: Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy (Small 3/2014) Small. 10: 417-417. DOI: 10.1002/Smll.201470016 |
0.354 |
|
| 2013 |
Leppert J, Liliental JE, Xu L, Thong AE, Yost C, Yaghi A, Brooks JD, Harshman LC, Sabatti C, Srinivas S, Felsher DW. Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 432. PMID 28136981 DOI: 10.1200/Jco.2013.31.6_Suppl.432 |
0.333 |
|
| 2013 |
Anso E, Mullen AR, Felsher DW, Matés JM, Deberardinis RJ, Chandel NS. Metabolic changes in cancer cells upon suppression of MYC. Cancer & Metabolism. 1: 7. PMID 24280108 DOI: 10.1186/2049-3002-1-7 |
0.429 |
|
| 2013 |
Nwabugwu CI, Rakhra K, Felsher DW, Paik DS. A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2013: 4529-32. PMID 24110741 DOI: 10.1109/EMBC.2013.6610554 |
0.319 |
|
| 2013 |
Rakhra K, Felsher DW. Generation of a tetracycline regulated mouse model of MYC-induced T-cell acute lymphoblastic leukemia. Methods in Molecular Biology (Clifton, N.J.). 1012: 221-35. PMID 24006068 DOI: 10.1007/978-1-62703-429-6_15 |
0.405 |
|
| 2013 |
Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, ... ... Felsher DW, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 122: 2864-76. PMID 23943652 DOI: 10.1182/Blood-2012-07-445635 |
0.389 |
|
| 2013 |
Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer Expert Opinion On Investigational Drugs. 22: 1495-1509. PMID 23937225 DOI: 10.1517/13543784.2013.829453 |
0.36 |
|
| 2013 |
Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, Felsher DW, Gambhir SS. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Molecular Cancer Therapeutics. 12: 1896-905. PMID 23825064 DOI: 10.1158/1535-7163.Mct-12-1243 |
0.389 |
|
| 2013 |
Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. Journal of Hepatology. 59: 1007-13. PMID 23796475 DOI: 10.1016/J.Jhep.2013.06.010 |
0.417 |
|
| 2013 |
Nwabugwu C, Rakhra K, Felsher D, Paik D. In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth Computational and Mathematical Methods in Medicine. 2013. PMID 23573174 DOI: 10.1155/2013/802512 |
0.462 |
|
| 2013 |
Casey SC, Bellovin DI, Felsher DW. Noncanonical roles of the immune system in eliciting oncogene addiction. Current Opinion in Immunology. 25: 246-58. PMID 23571026 DOI: 10.1016/J.Coi.2013.02.003 |
0.472 |
|
| 2013 |
Perry RH, Bellovin DI, Shroff EH, Ismail AI, Zabuawala T, Felsher DW, Zare RN. Characterization of MYC-induced tumorigenesis by in situ lipid profiling. Analytical Chemistry. 85: 4259-62. PMID 23560736 DOI: 10.1021/Ac400479J |
0.422 |
|
| 2013 |
Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research. 73: 1821-30. PMID 23467612 DOI: 10.1158/0008-5472.Can-12-2067 |
0.492 |
|
| 2013 |
Bisikirska BC, Adam SJ, Alvarez MJ, Rajbhandari P, Cox R, Lefebvre C, Wang K, Rieckhof GE, Felsher DW, Califano A. STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma. Oncogene. 32: 5283-91. PMID 23178486 DOI: 10.1038/Onc.2012.543 |
0.429 |
|
| 2013 |
Bellovin DI, Das B, Felsher DW. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Advances in Experimental Medicine and Biology. 734: 91-107. PMID 23143977 DOI: 10.1007/978-1-4614-1445-2_6 |
0.478 |
|
| 2013 |
Bellovin DI, Yevtodiyenko A, Adam SJ, Fernando H, Arzeno J, Gabay M, Felsher DW. Abstract LB-313: Development of a novel anti-MYC therapeutic with efficacy against liver and kidney cancers. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-313 |
0.827 |
|
| 2013 |
Altman BJ, Hsieh A, Gouw A, Venkataraman A, Li B, Bellovin D, Simon MC, Felsher D, Hogenesch J, Dang CV. Abstract 4616: Oncogenic c- and N-Myc disrupt circadian rhythm. Cancer Research. 73: 4616-4616. DOI: 10.1158/1538-7445.Am2013-4616 |
0.413 |
|
| 2013 |
Fan AC, Leppert J, Liliental JE, Xu L, Metzner TJ, Shroff E, Yaghi A, Yost C, Brooks JD, Harshman LC, Sabatti C, Srinivas S, Felsher DW. Abstract 2283: Nano-scale proteomic profiles of response to targeted therapy in patients with RCC. Cancer Research. 73: 2283-2283. DOI: 10.1158/1538-7445.Am2013-2283 |
0.409 |
|
| 2013 |
Wild A, Bellovin D, Chettiar ST, Gandhi N, Gajula RP, Williams RD, Cades JA, Amanda WJ, Felsher DW, Herman JM. Twist1 Overexpression Induces Increased Tumor Cell Aggressiveness and Resistance to Sorafenib in Hepatocellular Carcinoma Cells International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.1746 |
0.415 |
|
| 2012 |
Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. Plos One. 7: e45119. PMID 23024800 DOI: 10.1371/Journal.Pone.0045119 |
0.446 |
|
| 2012 |
Das B, Bayat-Mokhtari R, Tsui M, Lotfi S, Tsuchida R, Felsher DW, Yeger H. HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells (Dayton, Ohio). 30: 1685-95. PMID 22689594 DOI: 10.1002/Stem.1142 |
0.311 |
|
| 2012 |
Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, ... ... Felsher DW, et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. Plos Genetics. 8: e1002650. PMID 22654667 DOI: 10.1371/Journal.Pgen.1002650 |
0.429 |
|
| 2012 |
DeChristopher BA, Fan AC, Felsher DW, Wender PA. "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget. 3: 58-66. PMID 22308267 DOI: 10.18632/Oncotarget.438 |
0.378 |
|
| 2012 |
Bachireddy P, Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clinical and Experimental Immunology. 167: 188-94. PMID 22235994 DOI: 10.1111/J.1365-2249.2011.04514.X |
0.397 |
|
| 2012 |
Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J, Hannah J, Iqbal J, Anderson KM, Siebler HM, Smith LM, Greiner TC, Bastola D, Joshi S, Lockridge O, ... ... Felsher DW, et al. Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. The Journal of Clinical Investigation. 122: 163-77. PMID 22133874 DOI: 10.1172/Jci57292 |
0.456 |
|
| 2012 |
Fan AC, Banerjee P, Leppert J, Harshman LC, Sabatti C, Brooks JD, Felsher DW. Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens. Journal of Clinical Oncology. 30: 10513-10513. DOI: 10.1200/Jco.2012.30.15_Suppl.10513 |
0.38 |
|
| 2012 |
Fan AC, Banerjee P, Felsher DW. Abstract LB-443: The Simple Western rapidly generates quantitative profiles of MAPK and PI3K proteins in clinical specimens Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-443 |
0.344 |
|
| 2012 |
Lin W, Rajbhandari N, Liu C, Sakamoto K, Batra S, Opavsky R, Felsher D, Hollingsworth M, Hebrok M, Rui H, Wagner K. Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-429 |
0.467 |
|
| 2012 |
Adam SJ, Yetil A, Gevaert O, Jojic V, Gentles A, Felsher DW. Abstract 4879: Distinct roles of p53 and p19ARF in MYC-dependent tumor oncogene addiction Cancer Research. 72: 4879-4879. DOI: 10.1158/1538-7445.Am2012-4879 |
0.492 |
|
| 2012 |
Bellovin DI, Tran PT, Adam SJ, Gentles AJ, Wang XW, Felsher DW. Abstract 2975: Transgenic mouse model of Twist1-induced metastasis reveals genes highly prognostic for human hepatocellular carcinoma Cancer Research. 72: 2975-2975. DOI: 10.1158/1538-7445.Am2012-2975 |
0.444 |
|
| 2012 |
Fan AC, Banerjee P, Xu L, Kong C, Sabatti C, Wilhelm F, Greenberg P, Felsher DW. Abstract 1280: Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer Cancer Research. 72: 1280-1280. DOI: 10.1158/1538-7445.Am2012-1280 |
0.324 |
|
| 2011 |
Salih T, Aziz K, Thiyagarajan S, Armour M, Shanmugam B, Zeng J, Adam SJ, Felsher DW, DeWeese TL, Tran PT. Radiosensitization of MYC-overexpressing prostate cancer cells by statins. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 26. PMID 27968389 DOI: 10.1200/Jco.2011.29.7_Suppl.26 |
0.399 |
|
| 2011 |
Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, Felsher DW. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Science Translational Medicine. 3: 103ra99. PMID 21974937 DOI: 10.1126/Scitranslmed.3002018 |
0.422 |
|
| 2011 |
Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America. 108: 17432-7. PMID 21969595 DOI: 10.1073/Pnas.1107303108 |
0.485 |
|
| 2011 |
Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia. 25: 1882-90. PMID 21778999 DOI: 10.1038/Leu.2011.168 |
0.317 |
|
| 2011 |
Saddic LA, Wirt S, Vogel H, Felsher DW, Sage J. Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. Plos One. 6: e19758. PMID 21573126 DOI: 10.1371/Journal.Pone.0019758 |
0.489 |
|
| 2011 |
Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Research. 71: 2286-97. PMID 21262914 DOI: 10.1158/0008-5472.Can-10-3367 |
0.457 |
|
| 2011 |
Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, Mitchell BS. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. The Journal of Biological Chemistry. 286: 11035-46. PMID 21242306 DOI: 10.1074/Jbc.M110.208470 |
0.394 |
|
| 2011 |
Fan AC, Xu L, Sridhar KJ, Tran M, Banerjee P, Renschler JP, Tripuraneni R, Wilhelm F, Greenberg PL, Felsher DW. A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib), Blood. 118: 3808-3808. DOI: 10.1182/Blood.V118.21.3808.3808 |
0.323 |
|
| 2011 |
Lin W, Zhang Q, Opavsky R, DiMaio DJ, Felsher DW, Batra SK, Hollingsworth MA, Wagner K. Abstract 2384: A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma Cancer Research. 71: 2384-2384. DOI: 10.1158/1538-7445.Am2011-2384 |
0.462 |
|
| 2010 |
Müller J, Samans B, Riggelen JV, Fagà G, Peh KNR, Wei CL, Müller H, Amati B, Felsher D, Eilers M. TGFbeta-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas Cell Cycle. 9: 4622-4626. PMID 21127397 DOI: 10.4161/Cc.9.23.14211 |
0.382 |
|
| 2010 |
Nielsen CH, Kimura RH, Withofs N, Tran PT, Miao Z, Cochran JR, Cheng Z, Felsher D, Kjær A, Willmann JK, Gambhir SS. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Research. 70: 9022-30. PMID 21062977 DOI: 10.1158/0008-5472.Can-10-1338 |
0.317 |
|
| 2010 |
Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes & Cancer. 1: 597-604. PMID 21037952 DOI: 10.1177/1947601910377798 |
0.535 |
|
| 2010 |
Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 18: 485-98. PMID 21035406 DOI: 10.1016/J.Ccr.2010.10.002 |
0.433 |
|
| 2010 |
Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Research. 70: 9837-45. PMID 20935221 DOI: 10.1158/0008-5472.Can-10-2650 |
0.457 |
|
| 2010 |
Graves EE, Vilalta M, Cecic IK, Erler JT, Tran PT, Felsher D, Sayles L, Sweet-Cordero A, Le QT, Giaccia AJ. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4843-52. PMID 20858837 DOI: 10.1158/1078-0432.Ccr-10-1206 |
0.357 |
|
| 2010 |
Fan-Minogue H, Cao Z, Paulmurugan R, Chan CT, Massoud TF, Felsher DW, Gambhir SS. Noninvasive molecular imaging of c-Myc activation in living mice. Proceedings of the National Academy of Sciences of the United States of America. 107: 15892-7. PMID 20713710 DOI: 10.1073/Pnas.1007443107 |
0.418 |
|
| 2010 |
Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP. Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. Plos One. 5: e11367. PMID 20614008 DOI: 10.1371/Journal.Pone.0011367 |
0.378 |
|
| 2010 |
van Riggelen J, Müller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Möröy T, Felsher DW, Eilers M. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes & Development. 24: 1281-94. PMID 20551174 DOI: 10.1101/Gad.585710 |
0.404 |
|
| 2010 |
Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood. 115: 4061-70. PMID 20223922 DOI: 10.1182/Blood-2008-06-163386 |
0.393 |
|
| 2010 |
van Riggelen J, Felsher DW. Myc and a Cdk2 senescence switch. Nature Cell Biology. 12: 7-9. PMID 20027199 DOI: 10.1038/Ncb0110-7 |
0.425 |
|
| 2010 |
Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 161-70. PMID 19844192 DOI: 10.1038/Mt.2009.222 |
0.667 |
|
| 2010 |
Padua RA, Beurlet S, Krief P, Omidvar N, Pogam CL, Auboeuf D, de la Grange P, Soulie A, Janin A, Noguera M, Merlet P, Sarda-Mantel L, Fenaux P, Konopleva M, Andreeff M, ... ... Felsher DW, et al. ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival Blood. 116: 3308-3308. DOI: 10.1182/Blood.V116.21.3308.3308 |
0.388 |
|
| 2010 |
Fan AC, Dermody JL, Kong C, Zhang N, Xu L, Renschler JP, Orban MW, Varasteh B, Sridhar K, Natkunam Y, Coutre SE, Greenberg P, Felsher DW. Nanoscale approaches to define biologic signatures and measure proteomic response to targeted therapies in hematologic and solid tumors Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Pr6 |
0.46 |
|
| 2010 |
Adam SJ, Xu L, Karlsson A, Felsher DW. Abstract 5070: Identification of DKK2 as a candidate gene that facilitates tumor reoccurrence upon MYC inactivation Cancer Research. 70: 5070-5070. DOI: 10.1158/1538-7445.Am10-5070 |
0.507 |
|
| 2010 |
Bellovin DI, Adam SJ, Yang Q, Felsher DW. Abstract 5036: NF-κB pathway inhibition delays the onset of MYC-induced liver cancer Cancer Research. 70: 5036-5036. DOI: 10.1158/1538-7445.Am10-5036 |
0.428 |
|
| 2009 |
Fan AC, Orban MW, Shirer AE, Rajwanshi R, Kong C, Natkunam Y, Lee HE, Coutre S, Felsher DW. Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11011. PMID 27963976 DOI: 10.1200/Jco.2009.27.15_Suppl.11011 |
0.343 |
|
| 2009 |
Lee HG, Chen Q, Wolfram JA, Richardson SL, Liner A, Siedlak SL, Zhu X, Ziats NP, Fujioka H, Felsher DW, Castellani RJ, Valencik ML, McDonald JA, Hoit BD, Lesnefsky EJ, et al. Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. Plos One. 4: e7172. PMID 19779629 DOI: 10.1371/Journal.Pone.0007172 |
0.348 |
|
| 2009 |
Liu Z, Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, Dai H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angewandte Chemie (International Ed. in English). 48: 7668-72. PMID 19760685 DOI: 10.1002/Anie.200902612 |
0.345 |
|
| 2009 |
Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nature Medicine. 15: 566-71. PMID 19363496 DOI: 10.1038/Nm.1903 |
0.661 |
|
| 2009 |
Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG. SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjugate Chemistry. 20: 742-9. PMID 19320434 DOI: 10.1021/Bc800443W |
0.314 |
|
| 2009 |
Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC, Bailey AS, Fleming WH, Corless C, Felsher DW, Naumovski L, et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proceedings of the National Academy of Sciences of the United States of America. 106: 4390-5. PMID 19251665 DOI: 10.1073/Pnas.0809080106 |
0.453 |
|
| 2009 |
Lee HG, Casadesus G, Nunomura A, Zhu X, Castellani RJ, Richardson SL, Perry G, Felsher DW, Petersen RB, Smith MA. The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. The American Journal of Pathology. 174: 891-7. PMID 19164506 DOI: 10.2353/Ajpath.2009.080583 |
0.341 |
|
| 2009 |
Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tüting T, Barchet W, Büttner R, Limmer A, Gütgemann I. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology (Baltimore, Md.). 49: 471-81. PMID 19105207 DOI: 10.1002/Hep.22652 |
0.425 |
|
| 2009 |
Fan AC, Dermody JL, Kong C, Zhang N, Orban MW, Pai R, Xu L, Varasteh B, Tran M, Sridhar K, Lee L, Greenberg PL, Felsher DW. Abstract B178: Nanoscale quantification of phosphorylated and unphosphorylated ERK and MEK isoforms differentiates tumor and nontumor clinical specimens Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B178 |
0.412 |
|
| 2008 |
Fan AC, Orban M, Lee HE, Shirer AE, Rajwanshi R, Kong C, Natkunam Y, Coutre S, Felsher DW. Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8529. PMID 27951183 DOI: 10.1200/Jco.2008.26.15_Suppl.8529 |
0.402 |
|
| 2008 |
Felsher DW. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphatic Research and Biology. 6: 149-54. PMID 19093787 DOI: 10.1089/Lrb.2008.63403 |
0.505 |
|
| 2008 |
Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biology & Therapy. 7: 1947-51. PMID 18981708 DOI: 10.4161/Cbt.7.12.6947 |
0.763 |
|
| 2008 |
Felsher DW. Tumor dormancy and oncogene addiction. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 116: 629-37. PMID 18834407 DOI: 10.1111/J.1600-0463.2008.01037.X |
0.524 |
|
| 2008 |
Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Molecular Cancer. 7: 74. PMID 18826639 DOI: 10.1186/1476-4598-7-74 |
0.31 |
|
| 2008 |
Traykova-Brauch M, Schönig K, Greiner O, Miloud T, Jauch A, Bode M, Felsher DW, Glick AB, Kwiatkowski DJ, Bujard H, Horst J, von Knebel Doeberitz M, Niggli FK, Kriz W, Gröne HJ, et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature Medicine. 14: 979-84. PMID 18724376 DOI: 10.1038/Nm.1865 |
0.307 |
|
| 2008 |
Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance Cancer Research. 68: 5132-5142. PMID 18593912 DOI: 10.1158/0008-5472.Can-07-6192 |
0.441 |
|
| 2008 |
Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. Plos One. 3: e2493. PMID 18560566 DOI: 10.1371/Journal.Pone.0002493 |
0.68 |
|
| 2008 |
Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. Plos Genetics. 4: e1000090. PMID 18535662 DOI: 10.1371/Journal.Pgen.1000090 |
0.771 |
|
| 2008 |
Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. Plos One. 3: e2125. PMID 18461184 DOI: 10.1371/Journal.Pone.0002125 |
0.451 |
|
| 2008 |
Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Research. 68: 3081-6; discussion 3. PMID 18451131 DOI: 10.1158/0008-5472.Can-07-5832 |
0.478 |
|
| 2008 |
Kurobe M, Hu M, Beer S, Ghole S, Jeong YJ, Felsher D, Sylvester KG. 162. Oval Cell Expansion Through Wnt Signaling Shortens Tumor Latency During MYC Induced Hepatocarcinogenesis Journal of Surgical Research. 144: 249. DOI: 10.1016/J.Jss.2007.12.185 |
0.688 |
|
| 2007 |
Omidvar N, Kogan S, Beurlet S, le Pogam C, Janin A, West R, Noguera ME, Reboul M, Soulie A, Leboeuf C, Setterblad N, Felsher D, Lagasse E, Mohamedali A, Thomas NS, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Research. 67: 11657-67. PMID 18089795 DOI: 10.1158/0008-5472.Can-07-0196 |
0.379 |
|
| 2007 |
Opavsky R, Wang SH, Trikha P, Raval A, Huang Y, Wu YZ, Rodriguez B, Keller B, Liyanarachchi S, Wei G, Davuluri RV, Weinstein M, Felsher D, Ostrowski M, Leone G, et al. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. Plos Genetics. 3: 1757-69. PMID 17907813 DOI: 10.1371/Journal.Pgen.0030167 |
0.43 |
|
| 2007 |
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 104: 15400-5. PMID 17881568 DOI: 10.1073/Pnas.0706307104 |
0.478 |
|
| 2007 |
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 12: 230-8. PMID 17785204 DOI: 10.1016/J.Ccr.2007.08.004 |
0.319 |
|
| 2007 |
Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proceedings of the National Academy of Sciences of the United States of America. 104: 13028-33. PMID 17664422 DOI: 10.1073/Pnas.0701953104 |
0.48 |
|
| 2007 |
Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biology & Therapy. 6: 1318-23. PMID 17660712 DOI: 10.4161/Cbt.6.8.4508 |
0.447 |
|
| 2007 |
Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 110: 2674-84. PMID 17622571 DOI: 10.1182/Blood-2006-09-048033 |
0.445 |
|
| 2007 |
Arvanitis C, Bendapudi PK, Bachireddy P, Felsher DW. Identifying critical signaling molecules for the treatment of cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 172: 5-24. PMID 17607933 DOI: 10.1007/978-3-540-31209-3_2 |
0.778 |
|
| 2007 |
Pan M, Winslow MM, Chen L, Kuo A, Felsher D, Crabtree GR. Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. Journal of Immunology (Baltimore, Md. : 1950). 178: 4315-21. PMID 17371988 DOI: 10.4049/Jimmunol.178.7.4315 |
0.307 |
|
| 2007 |
Tran P, Lin J, Bendapudi P, Koh S, Komatsubara K, Horng G, Chen J, Shachaf C, Paik D, Felsher D. Predictive Modeling of Tumor Regression Kinetics Using a Murine Model of Oncogene-Addicted Lung Cancers International Journal of Radiation Oncology*Biology*Physics. 69: S596-S597. DOI: 10.1016/J.Ijrobp.2007.07.1898 |
0.449 |
|
| 2006 |
Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America. 103: 16266-71. PMID 17056717 DOI: 10.1073/Pnas.0608017103 |
0.461 |
|
| 2006 |
Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Seminars in Cancer Biology. 16: 313-7. PMID 16935001 DOI: 10.1016/J.Semcancer.2006.07.012 |
0.817 |
|
| 2006 |
Felsher DW. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle (Georgetown, Tex.). 5: 1808-11. PMID 16929172 DOI: 10.4161/Cc.5.16.3111 |
0.524 |
|
| 2006 |
Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes & Development. 20: 2096-109. PMID 16847353 DOI: 10.1101/Gad.1450406 |
0.352 |
|
| 2006 |
Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Research. 66: 6598-605. PMID 16818632 DOI: 10.1158/0008-5472.Can-05-3115 |
0.334 |
|
| 2006 |
Deb-Basu D, Karlsson A, Li Q, Dang CV, Felsher DW. MYC can enforce cell cycle transit from G1 to S and G 2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2 Cell Cycle. 5: 1348-1355. PMID 16760657 DOI: 10.4161/Cc.5.12.2860 |
0.36 |
|
| 2006 |
Deb-Basu D, Aleem E, Kaldis P, Felsher DW. CDK2 is required by MYC to induce apoptosis. Cell Cycle (Georgetown, Tex.). 5: 1342-7. PMID 16760655 DOI: 10.4161/Cc.5.12.2859 |
0.369 |
|
| 2006 |
Kampa KM, Acoba JD, Chen D, Beemer K, Gay J, Zhu Z, Padiernos E, Fan A, Felsher D, Corless C, Naumovski L, Lopez CD. ASPP2 Haploinsufficiency Promotes Tumor Formation in a Mouse Model. Blood. 108: 4333-4333. DOI: 10.1182/Blood.V108.11.4333.4333 |
0.391 |
|
| 2006 |
Fan AC, Deb-Basu D, Horoschak M, Shirer A, Voehringer D, O’Neill R, Felsher DW. Nano-Fluidic Detection of Oncoprotein Signaling in Preclinical and Patient Lymphoma Samples. Blood. 108: 2527-2527. DOI: 10.1182/Blood.V108.11.2527.2527 |
0.452 |
|
| 2005 |
Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, Greene WC. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. The Journal of Biological Chemistry. 280: 35713-22. PMID 16105841 DOI: 10.1074/Jbc.M504848200 |
0.354 |
|
| 2005 |
Beverly LJ, Felsher DW, Capobianco AJ. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Research. 65: 7159-68. PMID 16103066 DOI: 10.1158/0008-5472.Can-05-1664 |
0.412 |
|
| 2005 |
Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Letters. 226: 95-9. PMID 16039948 DOI: 10.1016/J.Canlet.2004.10.043 |
0.78 |
|
| 2005 |
Sander S, Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, Pollack JR. Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model Oncogene. 24: 6101-6107. PMID 16007205 DOI: 10.1038/Sj.Onc.1208751 |
0.395 |
|
| 2005 |
Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4278-81. PMID 15958607 DOI: 10.1158/1078-0432.Ccr-05-0534 |
0.344 |
|
| 2005 |
Shachaf CM, Felsher DW. Rehabilitation of cancer through oncogene inactivation. Trends in Molecular Medicine. 11: 316-21. PMID 15955741 DOI: 10.1016/J.Molmed.2005.05.003 |
0.529 |
|
| 2005 |
Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Research. 65: 4471-4. PMID 15930260 DOI: 10.1158/0008-5472.Can-05-1172 |
0.509 |
|
| 2005 |
Fan AC, Giuriato S, Karlsson A, Padua RA, Felsher DW. Two Oncogenic Hits Are Required To Initiate Lymphomagenesis in Adult, but Not Neonatal Hosts. Blood. 106: 2604-2604. DOI: 10.1182/Blood.V106.11.2604.2604 |
0.342 |
|
| 2004 |
Felsher DW. Putting oncogenes into a developmental context. Cancer Biology & Therapy. 3: 942-4. PMID 15611633 DOI: 10.4161/Cbt.3.10.1307 |
0.45 |
|
| 2004 |
Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 431: 1112-7. PMID 15475948 DOI: 10.1038/Nature03043 |
0.796 |
|
| 2004 |
Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, Felsher DW. Developmental context determines latency of MYC-induced tumorigenesis Plos Biology. 2. PMID 15455033 DOI: 10.1371/Journal.Pbio.0020332 |
0.804 |
|
| 2004 |
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proceedings of the National Academy of Sciences of the United States of America. 101: 14198-203. PMID 15375218 DOI: 10.1073/Pnas.0406138101 |
0.381 |
|
| 2004 |
Felsher DW. Reversibility of oncogene-induced cancer. Current Opinion in Genetics & Development. 14: 37-42. PMID 15108803 DOI: 10.1016/J.Gde.2003.12.008 |
0.433 |
|
| 2004 |
Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Seminars in Cancer Biology. 14: 3-11. PMID 14757531 DOI: 10.1016/J.Semcancer.2003.11.002 |
0.451 |
|
| 2004 |
Rabin K, Giuriato S, Ray S, Felsher DW. MYC Inactivation Induces Tumor Regression through the Recovery of a Functional DNA Damage Response. Blood. 104: 1534-1534. DOI: 10.1182/Blood.V104.11.1534.1534 |
0.489 |
|
| 2004 |
Fan AC, Giuriato S, Feng C, Padua RA, Felsher D. Cooperation between MYC and BCL2 to Induce Lymphoma Is Uncovered in an Adult Context. Blood. 104: 1530-1530. DOI: 10.1182/Blood.V104.11.1530.1530 |
0.44 |
|
| 2003 |
Felsher DW, Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News & Perspectives. 16: 370-4. PMID 12973448 DOI: 10.1358/Dnp.2003.16.6.829309 |
0.408 |
|
| 2003 |
Giuriato S, Felsher DW. How cancers escape their oncogene habit. Cell Cycle (Georgetown, Tex.). 2: 329-32. PMID 12851484 DOI: 10.4161/Cc.2.4.415 |
0.426 |
|
| 2003 |
Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nature Reviews. Cancer. 3: 375-80. PMID 12724735 DOI: 10.1038/Nrc1070 |
0.413 |
|
| 2002 |
Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101: 2797-803. PMID 12517816 DOI: 10.1182/Blood-2002-10-3091 |
0.466 |
|
| 2002 |
Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (New York, N.Y.). 297: 102-4. PMID 12098700 DOI: 10.1126/Science.1071489 |
0.818 |
|
| 2001 |
Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Molecular and Cellular Biology. 21: 3789-806. PMID 11340171 DOI: 10.1128/Mcb.21.11.3789-3806.2001 |
0.372 |
|
| 2000 |
Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 97: 10544-8. PMID 10962037 DOI: 10.1073/Pnas.190327097 |
0.382 |
|
| 1999 |
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Molecular Cell. 4: 199-207. PMID 10488335 DOI: 10.1016/S1097-2765(00)80367-6 |
0.494 |
|
| 1999 |
Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 96: 3940-4. PMID 10097142 DOI: 10.1073/Pnas.96.7.3940 |
0.401 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Lowe L, LaValley JW, Felsher DW. Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach. Cancer Drug Resistance (Alhambra, Calif.). 5: 917-925. PMID 36627896 DOI: 10.20517/cdr.2022.40 |
0.297 |
|
| 2010 |
van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature Reviews. Cancer. 10: 301-9. PMID 20332779 DOI: 10.1038/Nrc2819 |
0.295 |
|
| 2005 |
Padua R, Omidvar N, Kogan S, Phan T, West R, Felsher D, Weissmann I, Thomas S, Whittaker J, Janin A, Pla M, Muftis G, Bishop J, Chomienne C. O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS Leukemia Research. 29: S5. DOI: 10.1016/S0145-2126(05)80013-X |
0.29 |
|
| 2003 |
Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proceedings of the National Academy of Sciences of the United States of America. 100: 9974-9. PMID 12909717 DOI: 10.1073/Pnas.1732638100 |
0.289 |
|
| 2018 |
Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, Williams RD, Shiraishi T, Verdone J, Yildirir G, Henry R, ... ... Felsher D, et al. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. The Journal of Clinical Investigation. PMID 30130254 DOI: 10.1172/Jci94844 |
0.288 |
|
| 2004 |
Felsher DW. Oncogenes as therapeutic targets. Seminars in Cancer Biology. 14: 1. PMID 14757530 DOI: 10.1016/J.Semcancer.2003.11.001 |
0.287 |
|
| 2018 |
Heftdal LD, Swaminathan S, Felsher DW. Abstract 126: MYC-driven lymphomas suppress NK surveillance by blocking maturation of early NK cells Tumor Biology. DOI: 10.1158/1538-7445.Am2018-126 |
0.286 |
|
| 2016 |
Felsher DW, Lowe L. Affordable Cancer Medications Are Within Reach but We Need a Different Approach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 2194-5. PMID 27161965 DOI: 10.1200/Jco.2016.67.2436 |
0.284 |
|
| 1991 |
Felsher DW, Ando DT, Braun J. Independent rearrangement of Ig lambda genes in tissue culture-derived murine B cell lines. International Immunology. 3: 711-8. PMID 1911542 DOI: 10.1093/Intimm/3.7.711 |
0.281 |
|
| 2010 |
Zhou H, Rodriguez M, van den Haak F, Nelson G, Jogani R, Xu J, Zhu X, Xian Y, Tran PT, Felsher DW, Keall PJ, Graves EE. Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. International Journal of Radiation Oncology, Biology, Physics. 78: 297-305. PMID 20395069 DOI: 10.1016/J.Ijrobp.2009.11.008 |
0.28 |
|
| 2015 |
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, ... ... Felsher DW, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology. 35: S276-304. PMID 26590477 DOI: 10.1016/J.Semcancer.2015.09.007 |
0.275 |
|
| 2015 |
Taparra K, Wang H, Nugent K, Williams R, Malek R, Cades J, Felsher D, Tran P. Abstract 2291: Snai1 accelerates Kras driven lung tumorigenesis by overcoming oncogene-induced senescence Cancer Research. 75: 2291-2291. DOI: 10.1158/1538-7445.Am2015-2291 |
0.274 |
|
| 2014 |
Li Y, Casey SC, Choi PS, Felsher DW. miR-17-92 explains MYC oncogene addiction. Molecular & Cellular Oncology. 1: e970092. PMID 27308380 DOI: 10.4161/23723548.2014.970092 |
0.274 |
|
| 2019 |
Akiyama C, Tsumiyama K, Uchimura C, Honda E, Miyazaki Y, Sakurai K, Miura Y, Hashiramoto A, Felsher DW, Shiozawa S. Conditional Upregulation of IFN-α Alone Is Sufficient to Induce Systemic Lupus Erythematosus. Journal of Immunology (Baltimore, Md. : 1950). PMID 31324723 DOI: 10.4049/Jimmunol.1801617 |
0.274 |
|
| 2015 |
Kearney AY, Anchang B, Plevritis S, Felsher DW. ARF: Connecting senescence and innate immunity for clearance. Aging. PMID 26412380 |
0.271 |
|
| 2022 |
Gouw AM, Kumar V, Resendez A, Alvina FB, Liu NS, Margulis K, Tong L, Zare RN, Malhotra SV, Felsher DW. Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols. Acs Medicinal Chemistry Letters. 13: 615-622. PMID 35450373 DOI: 10.1021/acsmedchemlett.1c00673 |
0.271 |
|
| 2013 |
Nwabugwu CI, Rakhra K, Felsher DW, Paik DS. A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation Proceedings of the Annual International Conference of the Ieee Engineering in Medicine and Biology Society, Embs. 4529-4532. DOI: 10.1109/EMBC.2013.6610554 |
0.269 |
|
| 2024 |
Deutzmann A, Sullivan DK, Dhanasekaran R, Li W, Chen X, Tong L, Mahauad-Fernandez WD, Bell J, Mosley A, Koehler AN, Li Y, Felsher DW. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. Nature Communications. 15: 963. PMID 38302473 DOI: 10.1038/s41467-024-45128-y |
0.269 |
|
| 2013 |
Das B, Kashino SS, Pulu I, Kalita D, Swami V, Yeger H, Felsher DW, Campos-Neto A. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Science Translational Medicine. 5: 170ra13. PMID 23363977 DOI: 10.1126/Scitranslmed.3004912 |
0.268 |
|
| 2009 |
Nelson G, Rodriguez M, Zhou H, Lee A, Wu J, Tran P, Felsher D, Keall P, Graves E. SU-FF-J-162: In Vivo Biological Evaluation of Micro-CT Based 3D Conformal Radiotherapy System Medical Physics. 36: 2514-2514. DOI: 10.1118/1.3181455 |
0.267 |
|
| 2004 |
Yang Y, Contag CH, Felsher D, Shachaf CM, Cao Y, Herzenberg LA, Tung JW. The E47 transcription factor negatively regulates CD5 expression during thymocyte development Proceedings of the National Academy of Sciences of the United States of America. 101: 3898-3902. PMID 15001710 DOI: 10.1073/Pnas.0308764101 |
0.267 |
|
| 2012 |
Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leukemia Research. 36: 98-103. PMID 21924492 DOI: 10.1182/Blood.V116.21.4010.4010 |
0.265 |
|
| 2017 |
Gouw AM, Margulis K, Zare RN, Felsher DW. Metabolic aging by MYC: Distinct lipid accumulation and phospholipid suppression by MYC in lungs and kidneys detected by Desorption Electro Spray Ionization Mass Spectrometry Imaging (DESI-MSI) Experimental Gerontology. 94: 117. DOI: 10.1016/J.Exger.2017.02.038 |
0.264 |
|
| 2016 |
Taparra KT, Wang H, Malek R, Nugent K, Groves J, Yildirir G, Simons B, Felsher D, Zachara N, Tran PT. SNAI1 Regulates the Hexosamine Biosynthesis Pathway to Promote Kras Mutant Lung Tumorigenesis. International Journal of Radiation Oncology, Biology, Physics. 96: S54-S55. PMID 27675956 DOI: 10.1016/J.Ijrobp.2016.06.142 |
0.264 |
|
| 2014 |
Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, Felsher DW, Rao J. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nature Chemistry. 6: 519-26. PMID 24848238 DOI: 10.1038/Nchem.1920 |
0.263 |
|
| 2013 |
Das B, Tsuchida R, Bayat-Mokhtari R, Felsher D, Yeger H. Human embryonic stem cells exhibit altruistic behavior in the microenvironment of oxidative stress Cytotherapy. 15: S6. DOI: 10.1016/J.Jcyt.2013.01.019 |
0.259 |
|
| 2013 |
Leppert J, Fan A, Liliental J, Xu L, Thong A, Yost C, Yaghi A, Metzner T, Brooks J, Harshman L, Sabatti C, Srinivas S, Felsher D. 603 NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.154 |
0.257 |
|
| 2008 |
Tran P, Chen J, Choi P, Horng G, Felsher D. MYC Potentiates DNA Damage Response Dependent Cellular Senescence International Journal of Radiation Oncology*Biology*Physics. 72: S693. DOI: 10.1016/J.Ijrobp.2008.06.590 |
0.256 |
|
| 2021 |
Eguiarte-Solomon F, Blazanin N, Rho O, Carbajal S, Felsher DW, Tran PT, DiGiovanni J. Twist1 is required for the development of UVB-induced squamous cell carcinoma. Molecular Carcinogenesis. PMID 33713497 DOI: 10.1002/mc.23296 |
0.251 |
|
| 2020 |
Cui L, Gouw AM, LaGory EL, Guo S, Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, Bazhin AA, Chen M, Hu L, Xie J, Fang M, ... ... Felsher DW, et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nature Biotechnology. PMID 33077961 DOI: 10.1038/s41587-020-0707-9 |
0.246 |
|
| 1992 |
Braun J, Felsher DW, Goodglick LA. c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. Annals of the New York Academy of Sciences. 651: 467-9. PMID 1599133 DOI: 10.1111/J.1749-6632.1992.Tb24647.X |
0.24 |
|
| 2016 |
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, et al. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research. 50: 123-131. PMID 27736729 DOI: 10.1016/J.Leukres.2016.09.012 |
0.238 |
|
| 2012 |
Wu AR, Kawahara TLA, Rapicavoli NA, Riggelen JV, Shroff EH, Xu L, Felsher DW, Chang HY, Quake SR. High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation Lab On a Chip - Miniaturisation For Chemistry and Biology. 12: 2190-2198. PMID 22566096 DOI: 10.1039/C2Lc21290K |
0.235 |
|
| 2008 |
Tran PT, Felsher DW. The current STATe of biomarkers to predict the response to anti-angiogenic therapies. Cancer Biology & Therapy. 7: 2004-6. PMID 19158482 DOI: 10.4161/Cbt.7.12.7191 |
0.234 |
|
| 2017 |
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, et al. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. Leukemia Research. 59: 65. PMID 28575698 DOI: 10.1016/J.Leukres.2017.02.007 |
0.231 |
|
| 2012 |
To CA, Hsieh RW, McClellan JS, Howard W, Fischbein NJ, Brown JM, Felsher DW, Fan AC. Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. Bmj Case Reports. 2012. PMID 22962380 DOI: 10.1136/Bcr.08.2011.4578 |
0.227 |
|
| 2013 |
Felsher DW. Role of MYCN in retinoblastoma. The Lancet. Oncology. 14: 270-1. PMID 23498720 DOI: 10.1016/S1470-2045(13)70070-6 |
0.227 |
|
| 2020 |
Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers. Hepatology (Baltimore, Md.). PMID 33140851 DOI: 10.1002/hep.31614 |
0.219 |
|
| 2011 |
Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, Mitchell BS. Abstract 2069: Regulation of nucleostemin by reactive oxygen species Cellular and Molecular Biology. 71: 2069-2069. DOI: 10.1158/1538-7445.Am2011-2069 |
0.212 |
|
| 2022 |
Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, Kuruvilla S, Suresh A, Zhang J, Swamy V, Felsher DW. MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma that is Reversible Through Restoration of Pro-Inflammatory Macrophages. Cancer Research. PMID 36525476 DOI: 10.1158/0008-5472.CAN-22-0232 |
0.212 |
|
| 2010 |
Fan AC, Dermody J, Kong C, Zhang N, Colevas AD, Felsher DW. Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors. Journal of Clinical Oncology. 28: 2564-2564. DOI: 10.1200/Jco.2010.28.15_Suppl.2564 |
0.2 |
|
| 2010 |
Dejean E, Rénalier M, Foisseau M, Agirre X, De Paiva G, Al Saati T, Soulier J, Desjobert C, Lamant L, Felsher D, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F. R15 – Oral miR-16 participe à l’angiogenèse des tumeurs exprimant l’oncogène de fusion X-ALK Bulletin Du Cancer. 97: S22. DOI: 10.1016/S0007-4551(15)30932-2 |
0.19 |
|
| 2015 |
Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, Riggelen Jv, Plevritis S, Felsher DW. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia Oncotarget. 6: 3563-3577. |
0.179 |
|
| 1986 |
Welches W, Felsher D, Landshulz W, Maraganore JM. A rapid method for the purification of monomeric and/or dimeric phospholipases A2 in crotalid snake venoms. Toxicon : Official Journal of the International Society On Toxinology. 23: 747-54. PMID 4089870 DOI: 10.1016/0041-0101(85)90004-2 |
0.176 |
|
| 2016 |
Li Y, Deutzmann A, Felsher DW. BIM-mediated apoptosis and oncogene addiction. Aging. PMID 27688082 DOI: 10.18632/aging.101072 |
0.147 |
|
| 2021 |
Chen H, Shou K, Chen S, Qu C, Wang Z, Jiang L, Zhu M, Ding B, Qian K, Ji A, Lou H, Tong L, Hsu A, Wang Y, Felsher DW, et al. Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging. Advanced Materials (Deerfield Beach, Fla.). e2006902. PMID 33709533 DOI: 10.1002/adma.202006902 |
0.145 |
|
| 2022 |
Tong L, Shan M, Zou W, Liu X, Felsher DW, Wang J. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells. Frontiers in Oncology. 12: 904969. PMID 35978822 DOI: 10.3389/fonc.2022.904969 |
0.13 |
|
| 2023 |
Valenzi E, Bahudhanapati H, Tan J, Tabib T, Sullivan DI, Nouraie M, Sembrat J, Fan L, Chen K, Liu S, Rojas M, Lafargue A, Felsher DW, Tran PT, Kass DJ, et al. Single-Nucleus Chromatin Accessibility Identifies a Critical Role for TWIST1 in IPF Myofibroblast Activity. The European Respiratory Journal. PMID 37142338 DOI: 10.1183/13993003.00474-2022 |
0.107 |
|
| 2022 |
Lee CK, Atibalentja DF, Yao LE, Park J, Kuruvilla S, Felsher DW. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. Nanotheranostics. 6: 243-255. PMID 35145835 DOI: 10.7150/ntno.65544 |
0.076 |
|
| Hide low-probability matches. |